Cargando…

An integrative radiological, histopathological and molecular analysis of pediatric pontine histone-wildtype glioma with MYCN amplification (HGG-MYCN)

Detalles Bibliográficos
Autores principales:	Tauziède-Espariat, A., Debily, M-A, Castel, D., Grill, J., Puget, S., Sabel, M., Blomgren, K., Gareton, A., Dangouloff-Ros, V., Lechapt, E., Boddaert, N., Varlet, P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6556947/ https://www.ncbi.nlm.nih.gov/pubmed/31177990 http://dx.doi.org/10.1186/s40478-019-0738-y

Ejemplares similares

The pediatric supratentorial MYCN-amplified high-grade gliomas methylation class presents the same radiological, histopathological and molecular features as their pontine counterparts
por: Tauziède-Espariat, A., et al.
Publicado: (2020)

Refinement of diagnostic criteria for pediatric-type diffuse high-grade glioma, IDH- and H3-wildtype, MYCN-subtype including histopathology, TP53, MYCN and ID2 status
por: Tauziède-Espariat, Arnault, et al.
Publicado: (2023)

Pediatric high-grade glioma MYCN is frequently associated with Li-Fraumeni syndrome
por: Guerrini-Rousseau, Léa, et al.
Publicado: (2023)

NF2 and ZFTA evaluation in the diagnostic algorithm of pediatric posterior fossa ependymoma with H3K27ME3 retained expression
por: Tauziède-Espariat, Arnault, et al.
Publicado: (2023)

Deciphering the genetic and epigenetic landscape of pediatric bithalamic tumors
por: Tauziède‐Espariat, Arnault, et al.
Publicado: (2021)

EZHIP is a specific diagnostic biomarker for posterior fossa ependymomas, group PFA and diffuse midline gliomas H3-WT with EZHIP overexpression
por: Antin, C., et al.
Publicado: (2020)

The histomolecular criteria established for adult anaplastic pilocytic astrocytoma are not applicable to the pediatric population
por: Gareton, Albane, et al.
Publicado: (2019)

DIPG-58. HISTONE H3 WILD-TYPE DIPG/DMG OVEREXPRESSING EZHIP EXTEND THE SPECTRUM OF DIFFUSE MIDLINE GLIOMAS WITH PRC2 INHIBITION BEYOND H3-K27M MUTATION
por: Castel, David, et al.
Publicado: (2020)

Posterior fossa ependymoma H3 K27-mutant: an integrated radiological and histomolecular tumor analysis
por: Mariet, Cassandra, et al.
Publicado: (2022)

HGG-11. HIGH-GRADE GLIOMAS IN ADOLESCENTS AND YOUNG ADULTS HIGHLIGHT HISTOMOLECULAR DIFFERENCES WITH THEIR ADULT AND PAEDIATRIC COUNTERPARTS
por: Roux, Alexandre, et al.
Publicado: (2020)

Diagnostics of pediatric supratentorial RELA ependymomas: integration of information from histopathology, genetics, DNA methylation and imaging
por: Pagès, Mélanie, et al.
Publicado: (2018)

DIPG-35. BIOLOGICAL MEDICINE FOR DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) ERADICATION: RESULTS OF THE THREE ARM BIOMARKER-DRIVEN RANDOMIZED BIOMEDE 1.0 TRIAL
por: Grill, Jacques, et al.
Publicado: (2020)

DIPG-43. CLINICAL AND MOLECULAR CHARACTERISTIC OF A NEW SUBTYPE OF DMG, H3K27-ALTERED WITH MAPK-ACTIVATING CO-DRIVER MUTATIONS
por: Auffret, Lucie, et al.
Publicado: (2023)

MYCN and the epigenome
por: He, Stanley, et al.
Publicado: (2013)

DIPG-38. PATIENT-DERIVED THREE-DIMENSIONAL AVATARS REVEAL CELL-AUTONOMOUS MECHANISMS DRIVING INVASION AND METASTATIC PROGRESSION IN DIFFUSE MIDLINE GLIOMAS
por: Bruschi, Marco, et al.
Publicado: (2023)

Disseminated diffuse midline gliomas, H3K27-altered mimicking diffuse leptomeningeal glioneuronal tumors: a diagnostical challenge!
por: Tauziède-Espariat, Arnault, et al.
Publicado: (2022)

MYCN upregulates the transsulfuration pathway to suppress the ferroptotic vulnerability in MYCN-amplified neuroblastoma
por: Floros, Konstantinos V., et al.
Publicado: (2022)

MYCN is amplified during S phase, and c-myb is involved in controlling MYCN expression and amplification in MYCN-amplified neuroblastoma cell lines
por: Aygun, Nevim, et al.
Publicado: (2019)

DIPG-61. RESCUE REGIMENS AFTER BIOMEDE: POSSIBLE INFLUENCE ON OS ASSESSMENT
por: Carlo, Daniela Di, et al.
Publicado: (2020)

HGG-15. Generation of a novel mouse model for brain tumors of the DNA methylation class “GBM MYCN”
por: Schoof, Melanie, et al.
Publicado: (2022)

Implementation of the plasma MYCN/NAGK ratio to detect MYCN amplification in patients with neuroblastoma
por: Su, Yan, et al.
Publicado: (2020)

The genomic landscape of dysembryoplastic neuroepithelial tumours and a comprehensive analysis of recurrent cases
por: Pagès, Mélanie, et al.
Publicado: (2022)

Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors
por: Vaughan, Lynsey, et al.
Publicado: (2016)

MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma
por: Agarwal, Saurabh, et al.
Publicado: (2018)

Therapeutic potential of targeting MYCN: A case series report of neuroblastoma with MYCN amplification
por: Huang, Can, et al.
Publicado: (2020)

A MYCN-independent mechanism mediating secretome reprogramming and metastasis in MYCN-amplified neuroblastoma
por: Zhang, Hai-Feng, et al.
Publicado: (2023)

Papillary glioneuronal tumors: histological and molecular characteristics and diagnostic value of SLC44A1-PRKCA fusion
por: Pages, Melanie, et al.
Publicado: (2015)

Correlation Between MYCN Gene Status and MYCN Protein Expression in Neuroblastoma: A Pilot Study To Propose the Use of MYCN Immunohistochemistry in Limited-Resource Areas
por: Santiago, Teresa, et al.
Publicado: (2019)

The MYCN Protein in Health and Disease
por: Ruiz-Pérez, María Victoria, et al.
Publicado: (2017)

MYCN Function in Neuroblastoma Development
por: Otte, Jörg, et al.
Publicado: (2021)

MYCN and Metabolic Reprogramming in Neuroblastoma
por: Bansal, Mohit, et al.
Publicado: (2022)

Metastasis in neuroblastoma: the MYCN question
por: Bhavsar, Swapnil Parashram
Publicado: (2023)

MYCN-targeting miRNAs are predominantly downregulated during MYCN-driven neuroblastoma tumor formation
por: Beckers, Anneleen, et al.
Publicado: (2014)

Correction: MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma
por: Agarwal, Saurabh, et al.
Publicado: (2018)

Elimination of MYCN-Amplified Neuroblastoma Cells by Telomerase-Targeted Oncolytic Virus via MYCN Suppression
por: Tanimoto, Terutaka, et al.
Publicado: (2020)

Pediatric methylation class HGNET-MN1: unresolved issues with terminology and grading
por: Tauziède-Espariat, Arnault, et al.
Publicado: (2019)

An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability
por: Nagy, Zsuzsanna, et al.
Publicado: (2021)

A comprehensive analysis of infantile central nervous system tumors to improve distinctive criteria for infant‐type hemispheric glioma versus desmoplastic infantile ganglioglioma/astrocytoma
por: Tauziède‐Espariat, Arnault, et al.
Publicado: (2023)

New in vivo avatars of diffuse intrinsic pontine gliomas (DIPG) from stereotactic biopsies performed at diagnosis
por: Plessier, Alexandre, et al.
Publicado: (2017)

MYCN Amplifications and Metabolic Rewiring in Neuroblastoma
por: Pouliou, Marialena, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6a9mpps6ivmsuvj8scuq7q8sg2